Cargando…
The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II
AIMS: It is uncertain whether subclinical thyroid dysfunction is associated with cardiovascular disease (CVD) events and mortality in people with type 2 diabetes. The aim of this study was to determine whether undetected thyroid disease increases the risk of incident CVD and death in type 2 diabetes...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581822/ https://www.ncbi.nlm.nih.gov/pubmed/36083409 http://dx.doi.org/10.1007/s00592-022-01969-x |
_version_ | 1784812713670606848 |
---|---|
author | Chubb, S. A. Paul Peters, Kirsten E. Bruce, David G. Davis, Wendy A. Davis, Timothy M. E. |
author_facet | Chubb, S. A. Paul Peters, Kirsten E. Bruce, David G. Davis, Wendy A. Davis, Timothy M. E. |
author_sort | Chubb, S. A. Paul |
collection | PubMed |
description | AIMS: It is uncertain whether subclinical thyroid dysfunction is associated with cardiovascular disease (CVD) events and mortality in people with type 2 diabetes. The aim of this study was to determine whether undetected thyroid disease increases the risk of incident CVD and death in type 2 diabetes. METHODS: One thousand two hundred fifty participants with type 2 diabetes (mean age 65.3 years, 56.5% males, median diabetes duration 8.0 years) without known thyroid disease and not taking medications known to affect thyroid function were categorised, based on baseline serum free thyroxine (FT4) and thyrotropin (TSH) concentrations, as euthyroid, overt hypothyroid (increased TSH, low FT4), subclinical hypothyroid (increased TSH, normal FT4), overt thyrotoxic (decreased TSH, raised FT4) or subclinical thyrotoxic (decreased TSH, normal FT4). Incident myocardial infarction, incident stroke, all-cause and cardiovascular mortality were ascertained during a mean 6.2–6.7 years of follow-up. RESULTS: Most participants with newly-detected thyroid dysfunction had subclinical hypothyroidism (77.2%) while overt/subclinical thyrotoxicosis was infrequent. Compared to participants with TSH 0.34–2.9 mU/L, those with TSH > 5.1 mU/L were not at increased risk of incident myocardial infarction (adjusted hazard ratio (95% confidence limits) 1.77 (0.71, 2.87)), incident stroke (1.66 (0.58, 4.78)), all-cause mortality (0.78 (0.44, 1.37)) or cardiovascular mortality (1.16 (0.38, 3.58)). Independent baseline associates of subclinical hypothyroidism included estimated glomerular filtration rate and systolic blood pressure. CONCLUSIONS: Subclinical hypothyroidism was not independently associated with CVD events or mortality in community-dwelling people with type 2 diabetes despite its associations with CVD risk factors, questioning strategies to identify and/or treat mild thyroid dysfunction outside usual care. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00592-022-01969-x. |
format | Online Article Text |
id | pubmed-9581822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Milan |
record_format | MEDLINE/PubMed |
spelling | pubmed-95818222022-10-21 The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II Chubb, S. A. Paul Peters, Kirsten E. Bruce, David G. Davis, Wendy A. Davis, Timothy M. E. Acta Diabetol Original Article AIMS: It is uncertain whether subclinical thyroid dysfunction is associated with cardiovascular disease (CVD) events and mortality in people with type 2 diabetes. The aim of this study was to determine whether undetected thyroid disease increases the risk of incident CVD and death in type 2 diabetes. METHODS: One thousand two hundred fifty participants with type 2 diabetes (mean age 65.3 years, 56.5% males, median diabetes duration 8.0 years) without known thyroid disease and not taking medications known to affect thyroid function were categorised, based on baseline serum free thyroxine (FT4) and thyrotropin (TSH) concentrations, as euthyroid, overt hypothyroid (increased TSH, low FT4), subclinical hypothyroid (increased TSH, normal FT4), overt thyrotoxic (decreased TSH, raised FT4) or subclinical thyrotoxic (decreased TSH, normal FT4). Incident myocardial infarction, incident stroke, all-cause and cardiovascular mortality were ascertained during a mean 6.2–6.7 years of follow-up. RESULTS: Most participants with newly-detected thyroid dysfunction had subclinical hypothyroidism (77.2%) while overt/subclinical thyrotoxicosis was infrequent. Compared to participants with TSH 0.34–2.9 mU/L, those with TSH > 5.1 mU/L were not at increased risk of incident myocardial infarction (adjusted hazard ratio (95% confidence limits) 1.77 (0.71, 2.87)), incident stroke (1.66 (0.58, 4.78)), all-cause mortality (0.78 (0.44, 1.37)) or cardiovascular mortality (1.16 (0.38, 3.58)). Independent baseline associates of subclinical hypothyroidism included estimated glomerular filtration rate and systolic blood pressure. CONCLUSIONS: Subclinical hypothyroidism was not independently associated with CVD events or mortality in community-dwelling people with type 2 diabetes despite its associations with CVD risk factors, questioning strategies to identify and/or treat mild thyroid dysfunction outside usual care. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00592-022-01969-x. Springer Milan 2022-09-09 2022 /pmc/articles/PMC9581822/ /pubmed/36083409 http://dx.doi.org/10.1007/s00592-022-01969-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Chubb, S. A. Paul Peters, Kirsten E. Bruce, David G. Davis, Wendy A. Davis, Timothy M. E. The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II |
title | The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II |
title_full | The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II |
title_fullStr | The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II |
title_full_unstemmed | The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II |
title_short | The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II |
title_sort | relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: the fremantle diabetes study phase ii |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581822/ https://www.ncbi.nlm.nih.gov/pubmed/36083409 http://dx.doi.org/10.1007/s00592-022-01969-x |
work_keys_str_mv | AT chubbsapaul therelationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii AT peterskirstene therelationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii AT brucedavidg therelationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii AT daviswendya therelationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii AT davistimothyme therelationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii AT chubbsapaul relationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii AT peterskirstene relationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii AT brucedavidg relationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii AT daviswendya relationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii AT davistimothyme relationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii |